EGFR and non-small cell lung carcinoma: Based on retrospective data from the US Oncology Network data, Pan et al. estimated that 15.2% of patients with stage IV NSCLC underwent EGFR testing and that 50.0% of patients with stage IV EGFR-mutant tumors received erlotinib [34].